Horizon Pharma Moving Ahead of FDA Decision Print E-mail
By Brian Wilson, Contributor   
Friday, 20 July 2012 07:34
icon_marketmoverShares of the pain drug developer Horizon Pharma (NASDAQ:HZNP) have recently seen some huge moves to the upside as the FDA’s decision looms for the company’s rheumatoid arthritis treatment RAYOS gets closer. Even after a virtual doubling of the shares since June, the company is valued at modest $265 million.
Read more...
 
Undervalued Verisante Redies Commercial Launch of Platform To Fight Skin Cancer Epidemic Print E-mail
By M.E.Garza   
Thursday, 19 July 2012 06:32
icon_bmrlogo There is an epidemic of skin cancer and one emerging medical device firm is poised to capture a big market position and visibility as they prepare to launch a device which addresses this growing need.
Read more...
 
Medivation Building Value On Prostate Cancer Prospects And Takeover Speculation Print E-mail
By Brian Wilson, Contributor   
Thursday, 19 July 2012 04:28
icon_marketmoverMedivation (MDVN) is a single-drug drug developer that has been on an absolute tear since it released extremely positive results for its prostate cancer drug Enzalutamide (formerly known as MDV3100) in November 2011. Since the data was released, Medivation is up over 430% and continues to make new highs with a very stable uptrend.
Read more...
 
Trovagene may have solved the elusive Liquid Biopsy Print E-mail
By A.J. Deniken, Contributor   
Tuesday, 17 July 2012 12:55
icon_closerlookFor several decades, researches have been developing technology that will pinpoint cancer cells or DNA fragments (nucleic acids) in blood to detect cancer in patients.  Several factors have held this technology back; one the most difficult hurdles is the need for large amount of blood samples.
Read more...
 
Updated: Short-Term Penny Stock Trade With Potential For Nice Profits Print E-mail
By M.E.Garza   
Tuesday, 17 July 2012 10:00
icon_tradecatalystThis morning, BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI) announced the financing our readers had been anticipating. With net proceeds to BrainStorm of approximately $4.78 million. The next pending catalyst could send shares of the company higher.
Read more...
 
Despite Myrexis’ Appeal As Value Investment, More To Consider Print E-mail
By Brian Wilson, Contributor   
Monday, 16 July 2012 05:40
icon_StormyRideFollowing the broader market deep into the red throughout late May and June of 2012, the former drug developer Myrexis (MYRX) looks capable of a temporary relief rally despite the prevalent concerns about the company’s direction, but it will be difficult.
Read more...
 
Profit from Canadian-Based Biotechs and Specialty Pharmas: Philippa Flint Print E-mail
By George S. Mack of The Life Sciences Report   
Friday, 13 July 2012 08:12
Covering a wide variety of small biotech and pharma companies domiciled in Canada, Bloom Burton & Co. Research Analyst Philippa Flint discusses important biotech and specialty pharma names that she knows quite well and expects to be very profitable for investors.
Read more...
 
Video Q&A: Array Plans To Partner More Products Print E-mail
By Staff and Wire Reports   
Thursday, 12 July 2012 01:23
arrayvideothumbRon Squarer, Chief Executive of Array BioPharma (NASDAQ:  ARRY), sits down with biotech stock analyst David Moskowitz to discuss the company`s pipeline, positioning, and commercialization strategies.
Read more...
 
Trading the Top Triglyceride Challengers Print E-mail
By Brian Wilson, Contributor   
Wednesday, 11 July 2012 03:36
icon_marketmoverAfter soaring about 120% higher since the start of the year, shares of the Irish pharmaceutical company Amarin Corporation (AMRN) are now trading in anticipation of the PDUFA action date of July 26th, 2012.
Read more...
 
Can Exelixis Continue Making Big Moves? Print E-mail
By Brian Wilson, Contributor   
Tuesday, 10 July 2012 07:07
icon_newsnotesAfter releasing more clinical data on the angiogenic inhibitor cabozantinib (XL184) at ASCO 2012, shares of developer Exelixis, Inc. (NASDAQ:EXEL) have moved significantly higher reflecting newfound faith in the drug’s market prospects.
Read more...
 
<< Start < Prev 51 52 53 54 55 56 Next > End >>

Page 55 of 56

Newsletter